Radiology Groups Push Back on New Cancer Screening Guidelines - Summary - MDSpire

Radiology Groups Push Back on New Cancer Screening Guidelines

Radiology groups say the ACP's new screening recommendations conflict with nearly every major cancer organization and could cost thousands of lives annually.

  • By

  • Kerri Miller

  • April 17, 2026

  • 2 min

Share

Objective:

To address the concerns raised by radiology organizations regarding the updated breast cancer screening guidelines released by the American College of Physicians (ACP).

Key Findings:
  • The ACP's recommendations could lead to an estimated 10,000 additional breast cancer deaths annually in the US.
  • The ACR and SBI's position aligns with multiple national cancer organizations advocating for earlier and more frequent screenings.
  • Claims of overdiagnosis and false positives in the ACP's guidance are considered overstated by the radiology groups.
Interpretation:

The pushback from ACR and SBI highlights significant disagreement within the medical community regarding breast cancer screening protocols, emphasizing the importance of early detection.

Limitations:
  • The ACP guidelines apply only to average-risk, asymptomatic patients.
  • The debate does not encompass the full spectrum of breast cancer risk factors and patient demographics.
Conclusion:

The ACR and SBI urge clinicians to continue annual screening practices despite the ACP's new guidelines, reflecting a broader consensus among various cancer organizations.

Original Source(s)

Radiology Groups Push Back on New Cancer Screening Guidelines

  • by Kerri Miller

  • April 17, 2026

Related Content

AI Model May Help Decipher Malignant, Benign Breast Lesions on MRI

Model matches deep-learning accuracy and helps physicians reclassify benign breast lesions.

Reduced-Dose Radiation Shows Durable Control

Single-arm cohort findings contrast with interim results from NRG-HN005, underscoring ongoing uncertainty around treatment deintensification.

Whole-Body MRI: Evidence Gap Widens

Two radiologists argue the for-profit scan industry has outrun the evidence — and the math warrants scrutiny.